- Conduit Pharmaceuticals (CDT, Financial) files a composition of matter patent for AZD5904, potentially securing up to 20 years of intellectual property protection.
- The new patent covers a novel solid form with enhanced solubility, allowing for innovative formulation strategies.
- AZD5904 has completed five Phase 1 studies with a strong safety profile, showing expanded potential for clinical applications beyond male infertility.
Conduit Pharmaceuticals (NASDAQ: CDT) has announced the filing of a composition of matter patent for AZD5904, a clinical-stage myeloperoxidase (MPO) inhibitor. This new patent introduces a novel solid form of AZD5904, which boasts significantly enhanced solubility. This development allows for innovative formulation strategies that could extend the compound's application across a broader range of diseases.
The patent potentially offers Conduit up to 20 years of intellectual property protection, transforming AZD5904 from a limited-use asset primarily associated with idiopathic male infertility to a versatile therapeutic platform. Originally developed by AstraZeneca for multiple sclerosis and chronic obstructive pulmonary disease (COPD), AZD5904 has successfully completed five Phase 1 clinical trials. These studies demonstrated strong target engagement without major safety or tolerability concerns.
Preclinical studies have shown that AZD5904 improves sperm motility and penetration, positioning it as a promising candidate for treating idiopathic male infertility. With 15% of couples globally facing infertility challenges and male infertility contributing to 50% of these cases, AZD5904 could represent a significant market opportunity.
Dr. Andrew Regan, CEO of Conduit Pharmaceuticals, emphasized that this new patent application advances the lifecycle of AZD5904, unlocking new commercial potentials and enabling novel formulation strategies that align with specific disease mechanisms. This strategic move underpins Conduit's focus on broadening the clinical development applications of AZD5904, particularly in conditions driven by MPO-related inflammation.
